N
Naoki Kaneko
Researcher at Astellas Pharma
Publications - 27
Citations - 1290
Naoki Kaneko is an academic researcher from Astellas Pharma. The author has contributed to research in topics: Survivin & Diffuse large B-cell lymphoma. The author has an hindex of 14, co-authored 27 publications receiving 1111 citations.
Papers
More filters
Journal ArticleDOI
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Hiroshi Hirai,Yoshikazu Iwasawa,Megumu Okada,Tsuyoshi Arai,Toshihide Nishibata,Makiko Kobayashi,Toshifumi Kimura,Naoki Kaneko,Junko Ohtani,Kazunori Yamanaka,Hiraku Itadani,Ikuko Takahashi-Suzuki,Kazuhiro Fukasawa,Hiroko Oki,Tadahiro Nambu,Jian Jiang,Takumi Sakai,Hiroharu Arakawa,Toshihiro Sakamoto,Takeshi Sagara,Takashi Yoshizumi,Shinji Mizuarai,Hidehito Kotani +22 more
TL;DR: The discovery of a potent and selective small-molecule inhibitor of Wee1 kinase, MK-1775, and its data indicate that Wee1 inhibition provides a new approach for treatment of multiple human malignancies.
Journal ArticleDOI
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori,Naoki Kaneko,Yoko Ueno,Masaki Yamada,Ruriko Tanaka,Rika Saito,Itsuro Shimada,Kenichi Mori,Sadao Kuromitsu +8 more
TL;DR: Results indicate that gilteritinib may be an important next-generationFLT3 inhibitor for use in the treatment of FLT3 mutation-positive AML.
Journal ArticleDOI
Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models
Kentaro Yamanaka,Takahito Nakahara,Tomohiro Yamauchi,Aya Kita,Masahiro Takeuchi,Fumiko Kiyonaga,Naoki Kaneko,Masao Sasamata +7 more
TL;DR: In this article, the authors evaluated the therapeutic potential of YM155, a selective survivin suppressant, alone and in combination with docetaxel using human melanoma models.
Journal ArticleDOI
Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).
Gentaroh Suzuki,Toshifumi Kimura,Akio Satow,Naoki Kaneko,Junko Fukuda,Hirohiko Hikichi,Naoko Sakai,Shunsuke Maehara,Hiroko Kawagoe-Takaki,Mikiko Hata,Tomoko Azuma,Satoru Ito,Hiroshi Kawamoto,Hisashi Ohta +13 more
TL;DR: In this article, a highly potent and selective metabotropic glutamate receptor (mGluR) 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1 H -1,2, 3-triazol-4-yl]- N -isopropyl- N -methyl-3,6-dihydropyridine-1(2 H )-carboxamide (FTIDC), is described.
Journal ArticleDOI
Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.
Tomohiro Yamauchi,Naoto Nakamura,Masashi Hiramoto,Masatoshi Yuri,Hiroyuki Yokota,Masanori Naitou,Masahiro Takeuchi,Kentaro Yamanaka,Aya Kita,Takahito Nakahara,Isao Kinoyama,Akira Matsuhisa,Naoki Kaneko,Hiroshi Koutoku,Masao Sasamata,Masato Kobori,Masao Katou,Shuichi Tawara,Shigeki Kawabata,Kiyoshi Furuichi +19 more
TL;DR: In this experiment, it is demonstrated that p54(nrb) binds to the survivin promoter and regulates survivin expression, which might lead to development of its use as a novel potential target in cancers.